- Home
- ESPR vs BAND Comparison
ESPR vs BAND Comparison
Compare ESPR & BAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- BAND
- Stock Information
- Founded
- ESPR 2008
- BAND 2000
- Country
- ESPR United States
- BAND United States
- Employees
- ESPR N/A
- BAND N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- BAND Computer Software: Prepackaged Software
- Sector
- ESPR Health Care
- BAND Technology
- Exchange
- ESPR Nasdaq
- BAND Nasdaq
- Market Cap
- ESPR 445.6M
- BAND 473.2M
- IPO Year
- ESPR 2013
- BAND 2017
- Fundamental
- Price
- ESPR $2.83
- BAND $15.99
- Analyst Decision
- ESPR Buy
- BAND Buy
- Analyst Count
- ESPR 6
- BAND 6
- Target Price
- ESPR $6.50
- BAND $20.80
- AVG Volume (30 Days)
- ESPR 6.1M
- BAND 217.9K
- Earning Date
- ESPR 11-06-2025
- BAND 10-30-2025
- Dividend Yield
- ESPR N/A
- BAND N/A
- EPS Growth
- ESPR N/A
- BAND N/A
- EPS
- ESPR N/A
- BAND N/A
- Revenue
- ESPR $268,125,000.00
- BAND $758,106,000.00
- Revenue This Year
- ESPR $10.59
- BAND $2.48
- Revenue Next Year
- ESPR N/A
- BAND $13.24
- P/E Ratio
- ESPR N/A
- BAND N/A
- Revenue Growth
- ESPR N/A
- BAND 14.51
- 52 Week Low
- ESPR $0.69
- BAND $11.33
- 52 Week High
- ESPR $3.94
- BAND $23.00
- Technical
- Relative Strength Index (RSI)
- ESPR 78.99
- BAND 60.83
- Support Level
- ESPR $2.37
- BAND $14.97
- Resistance Level
- ESPR $2.73
- BAND $16.49
- Average True Range (ATR)
- ESPR 0.16
- BAND 0.59
- MACD
- ESPR 0.02
- BAND 0.13
- Stochastic Oscillator
- ESPR 99.32
- BAND 79.43
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About BAND Bandwidth Inc.
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.